Developing  innovative treatments

that may enable the nervous system
to repair itself

Developing  innovative treatments

that may enable the nervous system
to repair itself

We create innovative treatments for nervous system damage due to injury or disease.

NervGen Pharma

NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. The company’s lead target indication is spinal cord injury.

Learn more

View our Corporate Presentation

VIEW PRESENTATION

Stay Connected

Subscribe to our mailing list to stay up to date

The Latest

News Release

NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates

November 9, 2023

NervGen reported its financial and operational results for the third quarter ended September 30, 2023.  

Read More ›

News Release

Neuroscientist and NervGen Scientific Founder, Dr. Jerry Silver, Interviewed on ‘Remarkable People’ Podcast Hosted by Tech Luminary Guy Kawasaki

November 8, 2023

NervGen announced that renowned neuroscientist, Dr. Jerry Silver, inventor of NervGen’s lead drug candidate, NVG-291, and NervGen Scientific Advisor, joined Guy Kawasaki on his acclaimed podcast, “Remarkable People”.  

Read More ›

Article

Stroke drug improves memory and repairs injured brain tissue in mice

July 28, 2022

Unlike existing treatments that focus on rehabilitation or reducing the risk of an additional stroke, the experimental drug targets the "stickiness" that can prevent injured brain tissue from functioning as it should

Read More ›
View all